Bullfrog AI Announced Data From Its Preclinical Study Investigating The Anti-cancer Activity Of A Novel Prodrug Of Mebendazole For Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
Bullfrog AI has announced data from its preclinical study investigating the anti-cancer activity of a novel prodrug of Mebendazole for Glioblastoma. The study found that animals treated with BF-223 had an average survival time of 27.9 days, compared to 27.3 days for those treated with BF-222 and 23.4 days for those given a placebo.
September 26, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bullfrog AI's preclinical study results show potential for its novel prodrug of Mebendazole in treating Glioblastoma, which could positively impact the company's stock.
The positive results from Bullfrog AI's preclinical study indicate potential for its novel prodrug of Mebendazole in treating Glioblastoma. This could lead to increased investor interest in the company, potentially driving up the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100